The effect of zoledronic acid treatment on the prevention of secondary new vertebral compression fractures following percutaneous vertebroplasty

Comparison of Efficacy of zoledronic acid and other therapy on the prevention of subsequent vertebral compression fracture after percutaneous vertebroplasty in patients with high risk for subsequent vertebral compression fracture: prospective comparative analysis between zoledronic acid-treated group and other therapy (risendronate)-treated group

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0003919

Enrollment

Registered

2019-05-15

Start date

2019-05-30

Completion date

Unknown

Last updated

2019-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : zoledronic acid 5mg.100ml injection Risendronate (Actonel EC TAB 35mg)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) BMD: T score > -3.7 (2) PVP-treated patient for OVCF (3) Patients who meet all of the above criteria will be defined as the high risk group of secondary new compressionl fracture.

Exclusion criteria

Exclusion criteria: (1) Pathologic fracture: metastatic vertebral fracture, benign or malignant tumor of vertebral body (ex: multiple myeloma) (2) Spinal infection (3) Previous spinal surgery (4) Systemic disease result in osteoporosis (ex: Vitamin D deficiency, Diabetes Mellitus, previous paresis) (5) Patients with multiple compression fracture (6) Patients with atrial fibrillation

Design outcomes

Primary

Measure	Time frame
subsequent vertebral compression fracture after percutaneous vertebroplasty-treated osteoporotic vertebral compression fracture	—

Secondary

Measure	Time frame
Visual Analogue Scale score after percutaneous vertebroplasty	—

Countries

Korea, Republic of

Contacts

Public ContactHong-Jae Lee

The Catholic University of Korea, Daejeon St. Mary's Hospital

lhjoc9506@naver.com+82-42-220-9525

Outcome results